Electronic Cigarette-derived Oxidants and Cardiopulmonary Effects

Description

This is a pilot study on the impact of switching from cigarettes to Electronic Cigarettes (EC) on disease-related clinical symptoms and biomarkers of harm in smokers with preexisting Chronic Obstructive Pulmonary Disease (COPD). The researchers hypothesize that the smokers who switch to EC completely or significantly will experience reduced COPD symptoms, risks of exacerbations, and decreased levels of oxidative stress and inflammation.

Conditions

Chronic Obstructive Pulmonary Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a pilot study on the impact of switching from cigarettes to Electronic Cigarettes (EC) on disease-related clinical symptoms and biomarkers of harm in smokers with preexisting Chronic Obstructive Pulmonary Disease (COPD). The researchers hypothesize that the smokers who switch to EC completely or significantly will experience reduced COPD symptoms, risks of exacerbations, and decreased levels of oxidative stress and inflammation.

Translational Studies on Electronic Cigarette-derived Oxidants and Their Long-term Cardiopulmonary Effects

Electronic Cigarette-derived Oxidants and Cardiopulmonary Effects

Condition
Chronic Obstructive Pulmonary Disease
Intervention / Treatment

-

Contacts and Locations

Hershey

Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States, 17033

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Mild to moderate COPD
  • * Smokes a popular brand of cigarette
  • * Willing to use an e-cigarette to reduce cigarette smoking down to 75% of their daily baseline cigarette use
  • * Ability to read, write and understand English
  • * Ability to provide informed consent and attend study visits
  • * History of active, chronic drug abuse or alcohol abuse problems
  • * Actively changing smoking behavior
  • * Unwilling or unable to provide blood samples
  • * Pregnant, planning to become pregnant, or nursing
  • * Use of tobacco products other than cigarettes in the past 30 days
  • * Recent history (\< 6 months) of myocardial infarction (MI)
  • * Any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or drug therapy within the past year. Antiarrhythmic drugs include amiodarone, flecainide, IV ibutilide, IV lidocaine, procainamide, propafenone, quinidine, tocainide
  • * Hospitalization for heart failure (NY Heart Association III or IV) within the past year
  • * Uncontrolled hypertension
  • * Known allergy to vegetable glycerin and propylene glycol
  • * History of seizures or medications to prevent seizures

Ages Eligible for Study

21 Years to 74 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Milton S. Hershey Medical Center,

Rebecca Bascom, MD, PRINCIPAL_INVESTIGATOR, Penn State Health Hershey Medical Center

Raghu Sinha, PhD, PRINCIPAL_INVESTIGATOR, Penn State Health Hershey Medical Center

Study Record Dates

2024-11